Matthew J Sikora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8577193/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. Cancer Research, 2014, 74, 1463-1474.	0.4	122
2	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nature Communications, 2017, 8, 1865.	5.8	108
3	The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 538-545.	1.3	89
4	The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Research and Treatment, 2009, 115, 289-296.	1.1	74
5	Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Research, 2018, 20, 106.	2.2	69
6	Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular Carcinogenesis, 2019, 58, 1770-1782.	1.3	68
7	Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Research and Treatment, 2009, 117, 571-575.	1.1	63
8	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Research, 2018, 78, 6209-6222.	0.4	58
9	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Research, 2016, 18, 92.	2.2	56
10	Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. Endocrinology, 2016, 157, 3760-3766.	1.4	50
11	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. Npj Breast Cancer, 2019, 5, 19.	2.3	46
12	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clinical Cancer Research, 2017, 23, 3802-3812.	3.2	43
13	Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems. Steroids, 2013, 78, 568-575.	0.8	41
14	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	3.2	38
15	The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clinical Cancer Research, 2020, 26, 6362-6373.	3.2	32
16	Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. Journal of Biological Chemistry, 2019, 294, 19950-19966.	1.6	31
17	Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Research and Treatment, 2012, 134, 1027-1039.	1.1	26
18	High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecologic Oncology, 2016, 141, 348-356.	0.6	20

MATTHEW J SIKORA

#	Article	IF	CITATIONS
19	Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4. Cancers, 2020, 12, 2931.	1.7	20
20	Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Letters, 2019, 461, 21-30.	3.2	18
21	Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. Cancer Biology and Therapy, 2008, 7, 767-776.	1.5	17
22	Differential Regulation and Targeting of Estrogen Receptor Î \pm Turnover in Invasive Lobular Breast Carcinoma. Endocrinology, 2020, 161, .	1.4	17
23	Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. Endocrinology, 2016, 157, 4553-4560.	1.4	15
24	SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Research and Treatment, 2019, 175, 327-337.	1.1	12
25	The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. Breast Cancer Research and Treatment, 2016, 157, 23-30.	1.1	10
26	WNT4 Balances Development vs Disease in Gynecologic Tissues and Women's Health. Endocrinology, 2021, 162, .	1.4	10
27	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. Npj Breast Cancer, 2022, 8, 62.	2.3	10
28	Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. Molecular Cancer Research, 2021, 19, 1270-1282.	1.5	9
29	The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer. Hormones and Cancer, 2018, 9, 399-407.	4.9	6
30	Reliable Gene Expression Measurements from Fine Needle Aspirates of Pancreatic Tumors. Journal of Molecular Diagnostics, 2010, 12, 566-575.	1.2	5
31	Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models. Molecular Cancer Research, 2022, 20, 837-840.	1.5	3
32	CRISPR Fish Reel in Novel Roles for Estrogen Receptors in Reproduction. Endocrinology, 2017, 158, 2082-2083.	1.4	2
33	Making an IMPACT on Career Development for Early- and Mid-career Faculty. Endocrinology, 2021, 162, .	1.4	0
34	OR12-05 MDC1 Is a Novel Estrogen Receptor Co-Regulator in Invasive Lobular Carcinoma of the Breast. Journal of the Endocrine Society, 2020, 4, .	0.1	0